Document is current
Any future updates will be listed below
-
Authors
Helal, Clara
Djerroudi, Lounes
Ramtohul, Toulsie
Laas, Enora
Vincent-Salomon, Anne
Jin, Maxime
Seban, Romain-David
Bieche, Ivan
Bello-Roufai, Diana
Bidard, Francois-Clement
Cottu, Paul
Loirat, Delphine
Carton, Matthieu
Lerebours, Florence
Kiavue, Nicolas
Romano, Emanuela
Bonneau, Claire
Cabel, Luc
- License Information
-
More Information
Article History
Received: 6 November 2024
Accepted: 3 February 2025
First Online: 13 February 2025
Competing interests
: Dr. Helal, Dr. Djerroudi, Dr. Ramtohul, Dr. Seban, Dr. Carton, Pr. Bieche, Dr. Maxime Jin, Dr. Enora Laas, Dr. Claire Bonneau, and Dr. Luc Cabel do not declare a conflict of interest. Pr Anne Vincent-Salomon reported lectures honorarium: AstraZeneca, Daiichi Sankyo, Ibex, MSD, PRIMAA, Roche, Gilead; Advisory Board: AstraZeneca, Daiichi Sankyo, Ibex, PRIMAA, Roche; Research Funding: AstraZeneca, Ibex, MSD, MSD Avenir, Owkin; Stock option: Ibex. Dr Bello-Roufai reported Board from MSD, AstraZeneca, Lilly, Eisai, and travel fees: MSD, AstraZeneca, Eisai. Pr Bidard reported Research fundings: GE Healthcare, Pfizer, Prolynx, Menarini Silicon Biosystems, Merck KGaA, MSD, Novartis, Personalis, Pfizer, Roche, SAGA Diagnostics, and Tempus. Advisory boards for AstraZeneca, Daiichi-Sankyo, Exact Sciences, GE Healthcare, Gilead, Inatherys, Lilly, Menarini/Stemline, Novartis, Pfizer, Roche, SAGA Diagnostics; Speaker for AstraZeneca, Daiichi-Sankyo, Lilly, Menarini/Stemline, and Pfizer. Travel support from AstraZeneca, Daiichi-Sankyo, Pfizer, Novartis. Pr Cottu reported Honoraria: Pfizer, Roche, Lilly, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Novartis, and NanoString Technologies. Consulting or Advisory Role: Pfizer, Lilly. Research funding: Pfizer. Travel, accommodations, and expenses: Roche, Pfizer, and Lilly. Dr Loirat reported Honoraria: AstraZeneca, Gilead Sciences Inc, Eli Lilly and Company, and MSD. Consulting or advisory fees: 4D Pharma, AstraZeneca, Gilead Sciences Inc., Immunomedics, Eli Lilly and Company, MSD Oncology, Novartis AG, Pfizer Inc., and Roche. Funding for travel, accommodations, and expenses: AstraZeneca, Gilead Sciences Inc., MSD, Pfizer Inc., and Roche. Dr. Lerebours reported Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events: AstraZeneca, Eisai, Gilead, Daiichi Sankyo, Lilly, Menarini, Novartis, Roche, and Seagen. Support for attending meetings and/or travel: Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, and Seagen. Dr Kiavue reported a Travel Grant from Seagen. Dr. Romano reported Grants and other support from AstraZeneca, Replimune, Bristol Myers Squibb, and Fonds Amgen France pour la Science et l’Humain outside the submitted work.
